Lyell Immunopharma, Inc. (LYEL)

HashiCorp Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-334.52	-342.99	-234.63	-183.12	-250.22	-204.47
Depreciation & Amortization	18.05	19.63	20.25	18.02	13.62	4.29
Loss (Gain) From Sale of Assets	2.62	1.34	1.51	0.1	1.21	-4.88
Asset Writedown & Restructuring Costs	138.48	138.48	-	-	-	-
Loss (Gain) From Sale of Investments	-10.51	-1.71	3.33	1.15	38.35	0.54
Stock-Based Compensation	30.01	33.14	47.08	81.92	62.2	33.26
Other Operating Activities	-9.81	-7.17	-4.65	-5.62	4.57	10.72
Change in Accounts Payable	-4.78	-3.23	1.46	0.67	0.09	-0.28
Change in Unearned Revenue	-	-	-	-84.65	-10.51	-7.76
Change in Other Net Operating Assets	-4.66	0.11	1.96	1.97	14.43	7.7
Operating Cash Flow	-175.12	-162.39	-163.69	-169.56	-126.25	-160.87
Capital Expenditures	-0.68	-0.46	-2.69	-24.28	-65.5	-51.48
Cash Acquisitions	-31.35	-31.35	-	-	-	-
Investment in Securities	201.92	154.23	186.73	12.74	-56.07	-222.04
Investing Cash Flow	169.9	122.42	184.05	-11.54	-121.57	-273.52
Issuance of Common Stock	1.3	1.4	2.2	11.1	401.24	0.37
Repurchase of Common Stock	-	-0.08	-0.46	-0.46	-	-11.81
Financing Cash Flow	1.3	1.33	1.74	10.64	401.24	476.79
Net Cash Flow	-3.92	-38.64	22.1	-170.46	153.42	42.4
Free Cash Flow	-175.8	-162.86	-166.38	-193.83	-191.75	-212.36
Free Cash Flow Margin	-270455.38%	-266980.33%	-127984.62%	-228.89%	-1800.50%	-2737.94%
Free Cash Flow Per Share	-12.94	-12.46	-13.26	-15.69	-28.22	-320.34
Levered Free Cash Flow	-82.55	-67.56	-90.36	-53.9	-129.82	-128
Unlevered Free Cash Flow	-82.55	-67.56	-90.36	-53.9	-129.82	-128
Change in Net Working Capital	-7.23	-16.96	1.57	12.73	6.66	-23.25

Updated May 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q